Department of Pharmacy, Chengdu Fifth People's Hospital, Chengdu, 611130, China.
Medical Quality Control & Evaluation Department, Chengdu Fifth People's Hospital, Chengdu, 611130, China.
Future Med Chem. 2024 Aug 17;16(16):1705-1726. doi: 10.1080/17568919.2024.2380245. Epub 2024 Aug 5.
Adiposity and obesity-related proteins (FTO), the earliest identified mRNA -methyladenosine (mA) demethylases, are known to play crucial roles in several biological processes. Therefore, FTO is a promising target for anticancer treatment. Understanding the biological functions and regulatory mechanisms of FTO targets can serve as guidelines for drug development. Despite significant efforts to develop FTO inhibitors, no specific small-molecule inhibitors have entered clinical trials so far. In this manuscript, we review the relationship between FTO and various cancers, the small-molecule inhibitors developed against FTO targets from the perspective of medicinal chemistry and other fields, and describe their structural optimization process and structure-activity relationship, providing clues for their future development direction.
肥胖相关蛋白(FTO)是最早被鉴定出的 mRNA -甲基腺苷(mA)去甲基酶,已知在多种生物学过程中发挥着关键作用。因此,FTO 是一种很有前途的抗癌治疗靶点。了解 FTO 靶点的生物学功能和调控机制可以为药物开发提供指导。尽管已经做出了很大努力来开发 FTO 抑制剂,但到目前为止,还没有特定的小分子抑制剂进入临床试验。在本文中,我们综述了 FTO 与各种癌症的关系,从药物化学和其他领域的角度描述了针对 FTO 靶点开发的小分子抑制剂,并描述了它们的结构优化过程和构效关系,为它们的未来发展方向提供了线索。